Exclusive neuronal expression of SUCLA2 in the human brain

Arpád Dobolyi1, Elsebet Ostergaard2, Attila G. Bagó1,3, Tamás Dóczi4, Miklós Palkovits1,5, Aniko Gál6, Mária J Molnár6, Vera Adam-Vizi7 and Christos Chinopoulos2

1Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, 1094, Hungary; 2Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, Copenhagen, 2100, Denmark; 3National Institute of Neurosurgery, Budapest, 1145, Hungary; 4MTA-PTE Clinical MR Research Group, Department of Neurosurgery, University of Pécs, 7623, Pécs, Hungary; 5Human Brain Tissue Bank, Semmelweis University, Budapest, 1094, Hungary; 6Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, 1083, Hungary; 7Department of Medical Biochemistry, Semmelweis University, Hungarian Academy of Sciences-SE Laboratory for Neurobiochemistry, Budapest, 1094, Hungary

Address correspondence to: Dr. Christos Chinopoulos, Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary. Tel: +361 4591500 ext. 60024, Fax: +361 2670031. E-mail: chinopoulos.christos@eok.sote.hu

ABSTRACT

SUCLA2 encodes the ATP-forming β subunit (A-SUCL-β) of succinyl-CoA ligase, an enzyme of the citric acid cycle. Mutations in SUCLA2 lead to a mitochondrial disorder manifesting as encephalomyopathy with dystonia, deafness and lesions in the basal ganglia. Despite the distinct brain pathology associated with SUCLA2 mutations, the precise localization of SUCLA2 protein has never been investigated. Here we show that immunoreactivity of A-SUCL-β in surgical human cortical tissue samples was present exclusively in neurons, identified by their morphology and visualized by double labeling with a fluorescent Nissl dye. A-SUCL-β immunoreactivity co-localized >99% with that of the d subunit of the mitochondrial F0-F1 ATP synthase. Specificity of the anti-A-SUCL-β antiserum was verified by the absence of labeling in fibroblasts from a patient with a complete deletion of SUCLA2. A-SUCL-β immunoreactivity was absent in glial cells, identified by antibodies directed against the glial markers GFAP and S100. Furthermore, in situ hybridization histochemistry demonstrated that SUCLA2 mRNA was present in Nissl-labeled neurons but not glial cells labeled with S100. Immunoreactivity of the GTP-forming β subunit (G-SUCL-β) encoded by SUCLG2, or in situ hybridization histochemistry for SUCLG2 mRNA could not be demonstrated in either neurons or astrocytes. Western blotting of post mortem brain samples revealed minor G-SUCL-β immunoreactivity that was however, not upregulated in samples obtained from diabetic versus non-diabetic patients, as has been described for murine brain. Our work establishes that SUCLA2 is expressed exclusively in neurons in the human cerebral cortex.

INTRODUCTION

Succinyl-CoA ligase (SUCL) is a heterodimeric enzyme, composed of an invariant α subunit encoded by SUCLG1 and a substrate-specific β subunit, encoded by either SUCLA2 or SUCLG2. This dimer combination results in either an ATP-forming (EC 6.2.1.5) or a GTP-forming SUCL (EC 6.2.1.4). The enzyme is located in the mitochondrial matrix being part of the citric acid cycle, catalyzing the conversion of succinyl-CoA and ADP (or GDP) to CoASH, succinate and ATP (or GTP) (1). $\Delta G$ for this reaction is 0.07 kJ/mol and therefore it is
When SUCL proceeds in the direction towards succinyl-CoA, this product may follow heme- or ketone body metabolism (3), (4). On the other hand, the reaction proceeding towards ATP or GTP formation is termed 'substrate-level phosphorylation' and can occur in the absence of oxygen. Substrate-level phosphorylation during anoxia/ischemia rescues cells from cytosolic ATP depletion (5), (6), (7). GTP is a central regulator of cellular anabolism (8); in mitochondria, GTP is used by the protein synthesis machinery, the PEP carboxykinase isoform 2 and GTP-AMP phosphotransferase and other GTP-binding proteins (9). GTP salvage inside the matrix is critical because it is not transported through the inner mitochondrial membrane in higher organisms (10), (but see (11), (12)). Yeast is the only organism harboring a mitochondrial GTP/GDP translocase, and a homologue in higher organisms has not been identified (13), however, yeast lack the GTP-forming SUCL (14). GTP-forming SUCL may support ATP formation in the matrix through the concerted action with a mitochondrial isoform of a nucleotide diphosphate kinase known as nm23-H4; this kinase complexes with either ATP- or GTP forming SUCL (15), (16).

Considering the extensive involvement of succinyl-CoA ligase in vital biochemical pathways, it is not surprising that its deficiency leads to serious pathology. The disease phenotype matches the tissue-specific expression of its subunits: A-SUCL-β is highly expressed in skeletal muscle, brain and heart, while G-SUCL-β is barely detected in brain and muscle, but strongly expressed in liver and kidney (17). Accordingly, mutations in SUCLA2 (MIM ID#612073) results in Leigh's or a Leigh-like syndrome with onset of severe hypotonia in early childhood, muscular atrophy and sensorineural hearing impairment often leading to death during childhood. Neuroimaging findings include basal ganglia involvement, especially affecting the putamen and the caudate nuclei (18), demyelination and atrophy (19). SUCLA2 deficient patients show no abnormalities related to liver functions. Mutations in the α subunit-encoding SUCLG1 gene have been reported in 16 patients, (20), (21) and they are associated with a phenotype similar to that seen in patients with SUCLA2 deficiency, or a fatal infantile lactic acidosis. Mutations in the SUCLG2 gene have not been reported so far, and may be incompatible with life. SUCL deficiency is associated with mtDNA depletion, characterized by a massive reduction of mitochondrial DNA content. Three main clinical presentations of mtDNA depletion syndrome (MDS) are known: i) myopathic, ii) encephalomyopathic and iii) hepatocerebral, depending on the tissues affected and their residual mitochondrial DNA levels (22). SUCLA2 deficiency is associated with the encephalomyopathic tier. mtDNA depletion (15–40% residual amount) was found in the muscle samples of such patients (23). However, no mtDNA depletion was found in fibroblasts from patients with SUCLA2 deficiencies in (24), and in only two out of four patients in another study (18).

Data on brain biopsies from SUCLA2 deficiency patients are not available. In the most comprehensive study in terms of extensive biopsies from patients with MDS, samples were collected from muscle, liver, blood or fibroblasts, but not brain (25). Yet, in SUCLA2 deficiency it is the brain that seems to be the most vulnerable tissue, as SUCLG2 and nm23-H4 are only weakly expressed (26), (17). SUCL forms a physical complex with nm23-H4, the lack of which hinders the kinase function leading to a defect in the last step of the mitochondrial nucleotide salvage pathway (27), thus causing mtDNA depletion (20).

Fibroblasts and skeletal muscle are homogeneous tissues (despite the different categories of muscle fiber types); however the brain consists of several different cell types, the major categories being neurons and glial cells. There is an obvious gap of knowledge regarding the pathophysiology of SUCLA2 deficiency in the brain, the organ that suffers the most from this inborn error of metabolism. Analysis of expression of SUCLA2 in the human brain has been reported only once, but in that report cell- or region-specific expression was not investigated (17). In this study, we show unequivocally that SUCLA2 is expressed exclusively in the neurons of the human brain.

RESULTS

SUCLA2 immunoreactivity in the human frontal and temporal cortical samples

SUCLA2 antibody labeled a large number of cells in both the frontal and temporal cortex with no visible difference between the male and female human brain (Fig. 1A). The labeled cells were numerous in all layers of the cortices except layer I (Fig. 1A). The labeled cells demonstrated different morphologies. A number of large pyramidal cells were labeled but smaller cells also showed SUCLA2 immunoreactivity. In general, SUCLA2 immunoreactivity was present within the cell bodies as well as the proximal dendrites but not in the nuclei (Fig. 1A, B).
The specificity of SUCLA2 immunoreactivity was validated using human fibroblasts. Normal human fibroblasts were strongly labeled with the same procedure of SUCLA2 immunostaining as used in the human brain (Fig. 2A). In contrast, fibroblasts derived from a patient lacking SUCLA2 did not show SUCLA2 immunolabeling (Fig. 2B).

The absence of SUCLG2 immunoreactivity in the human frontal and temporal cortical samples
SUCLG2 immunolabeling was intense in human fibroblasts indicating the presence of G-SUCL-β in these cells (Fig. 2C), however, the apparent morphology of the mitochondrial network was different than that observed from A-SUCL-β immunodecoration. For comparison, we immunolabeled HEK 293 cells which exhibit a very high expression of SUCLG2 (29); confocal images of G-SUCL-β immunolabeling in the latter cells are shown in figure 2D. The same procedure or using more concentrated or more diluted antiserum resulted in no specific cellular labeling in the human frontal and temporal cortical samples (Fig. 1C), in accordance to the original report by the group of Lambeth (17). It is to be noted that SUCLG2 for humans exhibits transcript variants. However, all transcripts are identical in the region 1-396, except in position 220 (see supplemental figure 1). The antibody that we used to identify SUCLG2 (Abcam, Cat No: ab96172) was raised by immunizing rabbits with a recombinant fragment corresponding to a region within the N terminal amino acids 1-204 of human SUCLG2. Therefore, it should not be able to distinguish among transcript variants.

The mitochondrial localization of SUCLA2 immunoreactivity
The labeling of SUCLA2 within the neurons is punctate with a cellular localization resembling that of mitochondria, suggesting the presence of SUCLA2 immunoreactivity in this organelle (Fig. 3A1, B1). Although in situ mitochondria are normally filamentous, cellular stress as it maybe the case during handling of the specimen or simply postmortem delay will cause mitochondrial fragmentation, yielding a punctate appearance. To identify the mitochondrial presence of SUCLA2, co-localization studies were performed for ATPase subunit d. The distribution of ATPase subunit d delineated the expected distribution of mitochondria (Fig. 3A2, B2). Furthermore, an almost complete co-localization of SUCLA2 and ATPase subunit d and the absence of singly labeled structures indicate the exclusively mitochondrial localization of SUCLA2 (Fig. 3A3, B3).

Identification of cell types containing SUCLA2 immunoreactivity in the human temporal cortex
The distribution of SUCLA2-immunoreactive cells is similar to that of neurons: they are present in all layers of the temporal cortex but their density is small in layer I (Fig. 4A1, B1). SUCLA2 immunoreactivity was present in 88% of cells identified as neuron based on its larger, less irregular shape in Nissl staining (Fig. 4A2). In contrast, dark Nissl-labeled cells, possibly glial cells do not contain SUCLA2 at all (Fig. 4A2). Unfortunately, labeling with NeuN (clone BBS/NC/VH-H14) or neuron-specific enolase used for the immunocytochemical identification of neurons did not label our human brain sections consistently to confirm the neuronal location of SUCLA2 immunoreactivity. Instead, we used glial markers to confirm the absence of SUCLA2 immunoreactivity in these cell types. Indeed, a lack of co-localization of SUCLA2 and S100, an astrocyte marker suggested that SUCLA2 was absent in astrocytes (Fig. 4B, C). In addition, the glial marker GFAP also showed a different distribution from SUCLA2-immunoreactive cells and did not co-localize with SUCLA2 immunoreactivity (Fig. 5).

The presence of SUCLA2 but not SUCLG2 mRNA in the human temporal cortex
A single band appeared on gels following RT-PCR using all primer pairs specific to SUCLA2 and SUCLG2 when cDNA from human fibroblasts were used (Fig. 6A). However, when human temporal cortical cDNA was used, the same molecular weight products appeared only with SUCLA2 primers albeit with a smaller bandwidth. In contrast, SUCLG2 primers produced extremely faint bands. It must be noted that a cDNA clone containing a complete ORF for SUCLG2 obtained from the human hippocampus appears in the literature (30). In our RT-PCR experiments very weak signals may well originate from SUCLG2 mRNA of lymphocytes, endothelial cells or pericytes of vessels present in the specimen. The lengths of the PCR products were consistent with the lengths calculated from the position of the corresponding primer pair (Fig. 6A). PCR reactions without cDNA template were always included, and we did not detect bands in these negative controls (not shown).

The distribution of mRNA expression of SUCLA2 in the human temporal cortex
In situ hybridization histochemistry revealed the distribution of mRNA of SUCLA2 (Fig. 6B), whereas that of SUCLG2 was not detected in the human temporal cortex (Fig. 6C), in agreement with the immunohistochemistry and RT-PCR results shown above, and the earlier results by the group of Lambeth (17). This result also verifies that the absence of G-SUCL-β immunoreactivity is genuine, and does not reflect a technical limitation of the antibody in our immunohistochemistry and/or Western blotting protocols. The two antisense probes for SUCLA2 resulted in identical hybridization patterns; therefore, they will not be separately described. In the temporal cortex, all layers contained SUCLA2 mRNA whereas the corpus callosum did not show any labeling. The intensity of labeling was the highest in the pyramidal layers containing large pyramidal cells (Fig. 6B). The intensity of labeling was lower in layer VI and in the superficial layers. In particular, layer I contained only a small number of cells expressing SUCLA2. In the human temporal cortical brain sections labeled for SUCLA2 mRNA, Nissl-labeled cells as well as S100-immunoreactive cells were present. The distribution of Nissl-labeled neurons (Fig. 7A) was similar to that of SUCLA2-expressing cells, whereas S100-immunoreactive glial cells had a more even distribution pattern (Fig. 7B). Furthermore, high magnification pictures indicated that over 90% of Nissl-labeled neurons exhibited SUCLA2 mRNA (Fig. 7C) while 95% of SUCLA2 mRNA-expressing cells were identified as neurons based on Nissl labeling in the human temporal cortex. In contrast, the distribution of SUCLA2 mRNA-expressing cells was different from that of S100-immunoreactive cells in high magnification pictures (Fig. 7D) and SUCLA2 mRNA-expressing cells showed less than 5% co-localization with S100 immunoreactivity.

SUCLA2 and SUCLG2 immunoreactivities in homogenates from various brain regions

The antibody directed against SUCLA2 worked in immunohistochemistry protocols only from fresh human brain specimens. However, the antibody recognized reliably SUCLA2 in samples that have been preserved in our Brain Tissue Bank for prolonged periods of time which were processed for Western blotting. This provided the opportunity to examine the presence of SUCLA2 from several brain regions. As shown in figure 8 panel A, homogenate samples obtained from three different donors (Tables 1A and B) from temporal cortex, caudate nucleus, putamen, frontal cortex, white matter and cerebellar cortex tested positive for SUCLA2 immunoreactivity. Even though white matter does not contain neuronal cell bodies it still exhibited significant SUCLA2 immunoreactivity, probably originating from the mitochondria found along the axons. 'MB' signifies mouse brain homogenates from four different animals (numbered as 1, 2, 3 and 4). In this and the other panels of figure 8, β-actin immunoreactivity served as a loading control for all lanes.

The specificity of the SUCLA2 antibody is certified by the blot shown in panel B, where there was no immunoreactivity from fibroblasts of a patient suffering from complete deletion of the SUCLA2 gene.

SUCLG2 immunoreactivity (panel A) was extremely weak in the human brain samples, as compared to the mouse brain samples, in accordance with the results of previous Western blot experiments (6). As for the case of RT-PCR results, such weak SUCLG2 immunoreactivity in human brain homogenates may originate from trapped lymphocytes, endothelial cells or pericytes from vessels present in the specimen, and not being genuine to neurons or glial cells. Although there are no tissues available with null expression of SUCLG2 (as in the case for the fibroblasts from the patient suffering from complete deletion of the SUCLA2 gene), the fact that the bands obtained from mouse tissues and the human specimens appeared at the exact same molecular weight affords a reasonable degree of assurance that SUCLG2 immunoreactivity is indeed genuine.

In the rat brain, streptozotocin-induced diabetes upregulates GTP-forming succinyl CoA ligase activity more than 10 times (31). We therefore compared SUCLG2 and SUCLA2 immunoreactivity in brain tissue homogenates from four controls versus four patients that suffered from diabetes mellitus for several years (Tables 1C and D). The results are shown in panel C of figure 8: SUCLG2 immunoreactivity was not increased in the samples from the diabetic patients as compared to those from control subjects, also verified by densitometric analysis of the bands (not shown).

DISCUSSION

Here we have investigated the cell-specific expression of SUCLA2 and SUCLG2 in the human brain. The most important observation was that A-SUCL-β was present exclusively in neurons, and not in other cell types. This finding has strong physiological implications regarding the differential metabolism of neurons versus astrocytes in the human brain and pathological implications related to the impact of SUCLA2 deficiency on brain
functions, discussed below. Furthermore, our study pinpoints SUCLA2 as a reliable marker for neuronal mitochondria. By the same token, any report on the function or activity of ATP-forming succinyl CoA ligase in brain tissue should not apply for the whole brain, only for neurons. In the same line, intracellular pathological manifestations of the brain caused by SUCLA2 deficiency, such as mtDNA depletion, should only be sought in neurons.

An obvious pathophysiological implication for astrocytes lacking A-SUCL-\(\beta\) and therefore being incapable of ATP provision by matrix substrate-level phosphorylation, is that their mitochondria are more likely to engage in cytosolic ATP consumption (5) than neuronal mitochondria, during natural fluctuations of their membrane potentials (32). As an extension of this, astrocytic mitochondria should be more vulnerable than neuronal mitochondria in terms of relying on -in house- ATP reserves during energy crisis, such as during brain ischemia (33), (34), (35). To this end, the weak expression of nm23-H4 (26), together with the lack of G-SUCL-\(\beta\) expression in astrocytes preclude the possibility of matrix ATP formation through GTP transphosphorylation. Furthermore, the notion that both ATP- and GTP-forming succinyl-CoA ligase activity should exhibit an extremely low -if any- rate in human astrocytes, hints at peculiarities of the directionality of citric acid cycle in these cells (7). Although the citric acid cycle is branded as a "cycle", it does not necessarily operate as one (7). Succinate can be the end-product of a 'backflux' citric acid cycle (36), commencing from pyruvate that is converted to oxaloacetate by pyruvate carboxylase, an enzyme found only in astrocytes in the brain (37), (38). Congruent to this, astrocytes are known to produce and release large quantities of succinate (39).

Finally, in the absence of either ATP- or GTP-forming succinyl-CoA ligase, succinyl-CoA emerging from the \(\alpha\)-ketoglutarate dehydrogenase complex in astrocytic mitochondria could be further processed towards heme and/or ketone body metabolism, pathways which are fully operational in astrocytes (40), (41), or serve as cofactor for lysine succinylation (42), a wide-spread post-translational modification; this would also prevent a 'coenzyme A trap' in the form of succinyl-CoA.

MATERIALS AND METHODS

**Human brains:** Human brain samples were collected in accordance with the Ethical Rules for Using Human Tissues for Medical Research in Hungary (HM 34/1999) and the Code of Ethics of the World Medical Association (Declaration of Helsinki). Post mortem tissue samples were taken during brain autopsy. In addition, surgical brain samples were obtained from tissue removed during brain surgeries at the Department of Neurosurgery Medical School, University of Pécs in the framework of the Human Brain Tissue Bank, Budapest. For autopsy, brains were removed from the skull with a post mortem delay of 2–6 h. Prior written informed consent was obtained from the patients or from the next of kin for autopsies, which included the request to conduct neurochemical analyses. The protocols including analyses of tissue samples, were approved by institutional ethics committee of the Semmelweis University and the University of Pécs. The three surgical patients underwent the removal of brain tumors. The 11 subjects, whose brains were used in the autopsy study died without any known neurological or affective disorder. The medical history of the subjects was obtained from medical or hospital records, interviews with family members and relatives, as well as from pathological and neuropathological reports. All personal identifiers had been removed and samples were coded before the analyses of tissue.

Surgically dissected freshly frozen temporal cortical samples from a 66 year old woman were used for RT-PCR and the development of in situ hybridization probes. In situ hybridization histochemistry was performed in temporal cortical samples from this patient as well as in the temporal cortex from a 64 year old woman. Immunolabeling was performed using frontal cortical sample of a 58 year old man and temporal cortical samples from the 64 year old and the 66 year old woman; tissue blocks of the latter two patients were also used for in situ hybridization histochemistry. Surgical samples that underwent immediate freezing for situ hybridization histochemistry or immediate fixation for immunolabeling were used in histochemical techniques, because they provided markedly superior results for visualizing SUCLA2 expression and distribution as compared to post mortem samples.

For western blotting, autopsy samples from different brain regions of 11 subjects were obtained by microdissection. Individual brain nuclei were microdissected from postmortem brains (that have been rapidly frozen on dry ice and stored at \(-80^\circ\)C) using the micropunch technique (28). Briefly, brains were cut as 1.0-1.5 mm thick coronal sections, and individual brain regions and nuclei were removed by special punch needles with
an inside diameter of 1.0-3.5 mm, by using either a head magnifier or a stereomicroscope. The microdissected samples were collected in airtight plastic (Eppendorf) tubes and stored at -80 °C until further use. The temperature of brain sections and the microdissected samples was kept under 0 °C during the whole procedure. *Mouse brains:* wild type C57BL/6 mice were obtained from Jackson Laboratory (JAX® Mice repository, Bar Harbor, Maine, USA). The animals used in our study were of either sex and 5 and 6 months of age. Mice were housed in a room maintained at 20–22 °C on a 12-hour light–dark cycle with food and water available *ad libitum.* All experiments were approved by the Animal Care and Use Committee of the Semmelweis University (Egyetemi állatkísérleti bizottság). Mice were killed by cervical dislocation and their brains were removed and kept at -80 °C until further manipulations.

*Cell cultures:* Fibroblast cultures from skin biopsies from the patient with no SUCLA2 expression and control subjects were prepared. Cells were grown on poly-L-ornithine coated 25 mm round glass coverslips for 5-7 days, at a density of approximately 8*10^5 cells/cover slip in RPMI1640 medium (GIBCO, Life technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 2 mM glutamine and kept at 37°C in 5% CO2. The medium was also supplemented with penicillin, streptomycin and amphotericin (item A5955, Sigma-Aldrich St. Louis, MO, USA). HEK 293 cells were grown on poly-L-ornithine coated 25 mm round glass coverslips for 1-2 days, at a density of approximately 5*10^5 cells/cover slip in DMEM (GIBCO) plus glutamine plus 10% fetal calf serum and 1% streptomycin-penicillin.

*Tissue collection for immunolabeling:* For immunocytochemistry, brains were cut into 5-10 mm thick coronal slices and immersion fixed in 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) for 3-5 days. Subsequently, the blocks were transferred to PBS containing 0.1% sodium azide for 2 days to remove excess paraformaldehyde. Then the blocks were placed in PBS containing 20% sucrose for 2 days for cryoprotection, after which the blocks were frozen and cut into 50 µm thick serial coronal sections on a sliding microtome. Sections were collected in PBS containing 0.1% sodium azide and stored at 4 °C until further processing.

*DAB immunolabeling of brain sections:* Every fifth free-floating brain section of human temporal and frontal cortical blocks was immunostained for SUCLA2 and SUCLG2. The antibodies (at dilutions 1:80; 1:320; 1:1280; 1:5120) were applied for 48 h at room temperature, followed by incubation of the sections in biotinylated anti-rabbit secondary antibody (1:1000 dilution; Vector Laboratories, Burlingame, CA) and then in avidin-biotin-peroxidase complex (1:500; Vector Laboratories) for 2 h. Subsequently, the labeling was visualized by incubation in 0.02% 3,3-diaminobenzidine (DAB; Sigma), 0.08% nickel (II) sulfate and 0.001% hydrogen peroxide in PBS, pH=7.4 for 5 minutes. Sections were mounted, dehydrated and coverslipped with Cytoseal 60 (Stephens Scientific, Riverdale, NJ, USA).

*Double labeling of SUCLA2 in brains sections:* SUCLA2 was immunolabeled as for single labeling using 1:1000 dilution except for the visualization, which was performed with fluorescein isothiocyanate (FITC)-tyramide (1:8000) and H2O2 in 100 mM Trizma buffer (pH 8.0 adjusted with HCl) for 6 min. Subsequently, sections were placed in mouse anti-ATPase subunit d, (1:500), or mouse anti-S100, a marker of glial cells (1:500; Millipore, Bedford, MA), and developed with FITC-linked secondary antibody (1:100; Molecular Probes, Eugene, OR) for 2 h and washed. For the double labeling with Nissl staining, the sections were incubated in ‘Neurotrace’ red fluorescent Nissl stain (Molecular Probes) diluted to 1:30 for 2 hours, and washed in PBS overnight. For double labeling with glial fibrillary acidic protein (GFAP), a marker of glial cells, the sections were first incubated in mouse anti-GFAP (1:300; Santa Cruz Biotechnology, Delaware, CA, USA; cat. number: sc-33673) and developed with FITC-tyramide amplification immunofluorescence as described above for SUCLA2. Then, the anti-SUCLA2 antiserum was used at a 1:350 dilution and visualized by Alexa 594 donkey anti-mouse secondary antibody (1:500; Molecular Probes, Eugene, OR) for 2 h and washed. For the double labeling with Nissl staining, the sections were incubated in ‘Neurotrace’ red fluorescent Nissl stain (Molecular Probes) diluted to 1:30 for 2 hours, and washed in PBS overnight. For double labeling with glial fibrillary acidic protein (GFAP), a marker of glial cells, the sections were first incubated in mouse anti-GFAP (1:300; Santa Cruz Biotechnology, Delaware, CA, USA; cat. number: sc-33673) and developed with FITC-tyramide amplification immunofluorescence as described above for SUCLA2. Then, the anti-SUCLA2 antiserum was used at a 1:350 dilution and visualized by Alexa 594 donkey anti-rabbit secondary antibody (1:500; Molecular Probes). Finally, all sections with fluorescent labels were mounted on positively charged slides (Superfrost Plus, Fisher Scientific, Pittsburgh, PA) and coverslipped in antifade medium (Prolong Antifade Kit, Molecular Probes).

*Immunocytochemistry of cell cultures:* Immunocytochemistry of the fibroblast or HEK 293 cultures was performed by fixing the cells with 4% paraformaldehyde in PBS for 20 min, followed by permeabilization by 0.1% TX-100 (in PBS) for 10 min and several washing steps in between with PBS. Cultures were treated with 10% donkey serum overnight at 4 °C followed by bathing in 1% donkey serum and 1 µg/ml anti-SUCLA2 (Proteintech Europe Ltd, Manchester, UK) or 1 µg/ml anti-SUCLG2 (Abcam, Cambridge, UK) for 1 hour at room temperature. Cells were subsequently decorated by using the appropriate Cy2-linked secondary antibody (1:4,000, donkey anti-rabbit, Jackson Immunochemicals Europe Ltd, Cambridgeshire, UK) in the presence of 1% donkey serum.
Western blotting: Cultured fibroblasts were harvested by trypsinization. Frozen brain samples were thawed on ice in the presence of radioimmunoprecipitation assay buffer and a protease cocktail inhibitor containing: 0.5 mM 4- (2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 150 nM Aprotinin, 1 µM E-64, 0.5 mM EDTA disodium, and 1 µM Leupeptin, and homogenized with a Teflon pestle. The suspensions were centrifuged once at 10,000 g for 10 min, and the proteins present in the supernatants were separated by sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were transferred to a methanol-activated polyvinylidene difluoride membrane. Immunoblotting was performed as recommended by the manufacturers of the antibodies. Rabbit polyclonals anti-SUCLG2 (Abcam, Cambridge, UK), and anti-SUCLA2 primary antibodies were used at concentrations of 1 µg/ml, and rabbit polyclonal anti-β actin (Abcam) at 0.1 µg/ml. Immunoreactivity was detected using the appropriate peroxidase-linked secondary antibody (1:4,000, donkey anti-rabbit, Jackson Immunochemicals Europe Ltd, Cambridgeshire, UK) and enhanced chemiluminescence detection reagent (ECL system; Amersham Biosciences GE Healthcare Europe GmbH, Vienna, Austria).

RT-PCR: RNA was isolated from surgically dissected human temporal cortex and cultured human fibroblasts. The surgical brain tissue sample was quickly frozen on dry ice and kept at -80°C until RNA isolation. The fibroblasts were centrifuged and resuspended in PBS immediately before RNA isolation. Both the brain surgical samples and the fibroblasts were homogenized in Trizol® Reagent (Invitrogen, Carlsbad, CA, USA) and RNA was isolated according to the manufacturer’s instructions. After diluting RNA to 1 µg/µl, it was treated with Amplification Grade DNase I (Invitrogen) and cDNA was synthesized with a Superscript II reverse transcriptase kit (Invitrogen) according to the manufacturer’s instructions. After 10-fold dilution, 2.5 µl of the resulting cDNA was used as template in PCR reactions performed with iTaq DNA polymerase (Bio-Rad Laboratories, Hercules, CA, USA) in total volumes of 12.5 µl under the following conditions: 95 °C for 3 min, followed by 35 cycles of 95 °C for 0.5 min, 60 °C for 0.5 min and 72 °C for 1 min. Primers were used at 300 nM final concentration for SUCLA2 (primer pair A: CCAGCAGATCTTCTTGATGT and TCAGTGCTTAGCATCATCG, primer pair B: TGCAGTGCTTCCTGAAAGCA and TCACTCTTTCCTGGTCCAGTC), primer pair C: GCAGCAGAAACATGTGCA and CCATCGAGGCCCATGTTAGT), and SUCLG2 (primer pair A: GAAGCTCTCAGGCTGTCAA and GTCCATCAAGAATTGCCAGGT, primer pair B: CCGTCTGGTAACACTCAG and AATGATGCCACAGTTGACGA, primer pair C: GGTCTCAAGGCGATTCAATTA and TATCCAAAGCTTCAAC, primer pair D: CATTGCTGTITTTGTAATG and AATGATGCCACAGTTGACGA). The calculated lengths of the PCR products are 235, 309, and 242 base pairs (bp) for human SUCLA2 and SUCLG2 were purified from gel in order to obtain non-overlapping probes to demonstrate specific labeling. The purified PCR products were inserted into TOPO TA cloning vectors (Invitrogen) according to the manufacturer’s instructions. Plasmids were purified from 5-7 colonies and applied as templates in PCR reactions with the specific primer pairs to select plasmids containing specific inserts. A positive plasmid for each probe was applied as template in PCR reactions, using primer pairs specific for the probe and also containing T7 RNA polymerase recognition site (GTAATACGACTCACTATAGGGCGAATTGGGTA) added to the reverse primers. Finally, the identities of the cDNA probes were verified by sequencing them with T7 primers.

Preparation of in situ hybridization probes: The PCR products using primer pairs A and B for both SUCLA2 and SUCLG2 were purified from gel in order to obtain non-overlapping probes to demonstrate specific labeling. The purified PCR products were inserted into TOPO TA cloning vectors (Invitrogen) and transformed chemically into competent bacteria according to the manufacturer’s instructions. Plasmids were purified from 5-7 colonies and applied as templates in PCR reactions with the specific primer pairs to select plasmids containing specific inserts. A positive plasmid for each probe was applied as template in PCR reactions, using primer pairs specific for the probe and also containing T7 RNA polymerase recognition site (GTAATACGACTCACTATAGGGCGAATTGGGTA) added to the reverse primers. Finally, the identities of the cDNA probes were verified by sequencing them with T7 primers.

In situ hybridization histochemistry: Surgically dissected temporal cortical brain samples from 2 patients were quickly frozen on dry ice, and kept at -80°C. Serial coronal sections (12 µm thick) were cut using a cryostat, mounted on positively charged slides (Superfrost Plus), dried, and stored at -80°C until use. [35S]UTP-labeled riboprobes were generated from the DNA probes containing T7 RNA polymerase recognition sites using a MAXIscript transcription kit (Ambion, Austin, TX, USA). The preparation of tissue was performed using mRNA locator Kit (Ambion), according to the manufacturer’s instructions. For hybridization, we used 80 µl hybridization buffer (mRNA locator Kit; Ambion) and labeled probes of 1 million DPM activity per slide. Washing procedures included a 30 min incubation in RNase A followed by decreasing concentrations of sodium-
citrate buffer (pH=7.4) at room temperature and subsequently at 65°C. Following successive dehydration and drying, the slides were dipped in 'NTB' nuclear track emulsion (Eastman Kodak, Rochester, NY, USA) and stored at 4°C for 3 weeks. Then the slides were developed and fixed with Kodak Dektol developer and Kodak fixer, respectively, counterstained with Giemsa, and coverslipped with Cytoseal 60 (Stephens Scientific). A cell was considered to express SUCLA2 or SUCLG2 if the number of autoradiography grains accumulated in a seemingly Gaussian distribution around a center was at least 3 times higher than the background level in an area corresponding to an average cell size (a circle with a diameter of 25 μm) in the same section. The background typically consisted of 1 - 3 grains per cell.

**Combination of in situ hybridization histochemistry with Nissl staining:** Slide attached sections of fresh temporal cortical brain tissue were first processed for in situ hybridization, as described above. After development, the sections were stained with 0.1% cresyl-violet dissolved in PBS, and then immersed in 96% ethanol containing 0.01% acetic acid. Alternatively, the sections were incubated in 'Neurotrace' red fluorescent Nissl stain (Molecular Probes,) diluted to 1:30 for 2 hours, washed in PBS overnight, and coverslipped in antifade medium (Prolong Antifade Kit, Molecular Probes). A cell was considered glial if it was dark labeled, and had a small diameter round-shape appearance. In turn, neurons exhibited less intense labeling, were larger and their shape was less regularly rounded. A cell was considered SUCLA2-expressing if it met the criteria described above for single label in situ hybridization histochemistry. A SUCLA2-expressing cell was considered Nissl-labeled if at least 70% of the area of the circle containing the accumulation of autoradiography grains contained Nissl labeling, and the center of the autoradiography grains was within the Nissl labeling.

**Combination of in situ hybridization histochemistry with S100 immunohistochemistry:** Slide-attached sections (20 μm thick) of fixed temporal cortical brain brains were first processed for in situ hybridization, as described above. Thus, tightly bound RNA-RNA pairs were already formed by the time immunohistochemistry was performed, immediately before dipping the slides into autoradiographic emulsion. In addition, the solutions used for perfusion and immunohistochemistry were prepared with DAPC-treated RNase-free water, which ensured that the labeling intensity of the in situ hybridization histochemistry did not decrease significantly. The immunolabeling protocol for S100 was the same as that described above for double labeling immunohistochemistry. Immunoreactivity was visualized using DAB reactions, after which the in situ hybridization procedure was continued by dipping the slides into the emulsion. Each double labeling experiment included controls, which was carried out through the double labeling procedure without application of radioactive in situ hybridization probes. These controls demonstrated that the DAB signal did not induce an autoradiography signal. A SUCLA2-expressing cell was considered S100-immunopositive if at least 70% of the area of the circle containing the accumulation of autoradiography grains contained immunoreactivity for S100 and the center of the autoradiography grains was within the immunolabeled cell.

**Image processing:** The sections were examined using an Olympus BX60 light microscope equipped with bright-field, dark-field and fluorescence. Images were captured at 2048 x 2048 pixel resolution with a SPOT Xplorer digital CCD camera (Diagnostic Instruments, Sterling Heights, MI, USA) using a 4x objective for dark-field images, and 4-40x objectives for bright-field and fluorescent images. **Fluorescent sections** were also evaluated using a Bio-Rad 2100 Rainbow Confocal System (Bio-Rad Laboratories, Inc, CA, USA). The contrast and sharpness of the images were adjusted using the “levels” and “sharpness” commands in Adobe Photoshop CS 8.0. Full resolution was maintained until the photomicrographs were finally cropped at which point the images were adjusted to a resolution of 300 dpi.

**Analysis of double immunolabeling:** Three 1 x 1 mm areas of double-labeled remote sections from each brain were randomly selected. The total number of SUCLA2-positive neurons with an identifiable cell nucleus and the number of double labeled cells was counted using a 20x objective of an Olympus BX60 light microscope equipped with fluorescent epi-illumination and a filter allowing for visualization of both green and red colors. Subsequently, the number of single labeled cells was also calculated in the area.

ACKNOWLEDGEMENTS: Thanks are expressed to Katalin Zölde for excellent technical assistance.

FUNDING: This work was supported by the Országos Tudományos Kutatási Alapprogram (OTKA) grants NNF2 85612, K 100319 to A.D., the Danish National Health Research Council grant 12-127702 to E.O., OTKA 81983 and the Hungarian Academy of Sciences grant 02001 to V. A.-V, TAMOP 4.2.1./B-09/1/KMR and BIOINF09TÉT_10-1-2011-0058 to MJM, OTKA grants NNF 78905, NNF2 85658, K 100918, and the MTA-SE Lendület Neurobiochemistry Research Division grant 95003 to C.C.
CONFLICT OF INTEREST STATEMENT: The authors declare no conflict of interests.

Reference List


**FIGURE LEGENDS**

Fig. 1. Immunolabeling for SUCLA2 but not SUCLG2 in the human temporal cortex. A: SUCLA2-immunoreactive cells with DAB visualization are evenly distributed in layer V. of the human temporal cortex. B: a large magnification picture demonstrates a distribution of SUCLA2 immunoreactivity that resembles to that of mitochondria within a labeled cell. C: SUCLG2 immunoreactivity is absent in the human temporal cortex. Scale bars = 50 µm for A and C, and 10 µm for B.

Fig. 2. Immunolabeling of human fibroblasts (SUCLA2, SUCLG2) and HEK 293 cells (SUCLG2). A: SUCLA2 immunoreactivity in normal human fibroblasts. Intracellular structures resembling mitochondria are intensely labeled. B: Specific labeling for SUCLA2 is absent in fibroblast derived from patients lacking SUCLA2. C: SUCLG2 labels normal human fibroblasts, albeit with a different pattern than that of SUCLA2. D: SUCLG2 labels HEK 293 cells with the same pattern as SUCLG2 in normal human fibroblasts. Scale bar for A, B and C = 50 µm. Scale bar for D= 10 µm.

Fig. 3. The mitochondrial localization of SUCLA2 based on its co-localization with ATPase subunit d. A1: SUCLA2 immunoreactivity in the human temporal cortex visualized by FITC-tetramide amplification immunofluorescence. Red blood cells in some capillaries are labeled because of their endogenous peroxidase activity. B1: a high magnification confocal image demonstrates the localization of SUCLA2 within a SUCLA2-positive cell. A2: Distribution of the immunoreactivity of the mitochondria marker ATPase subunit d in the same field as A1. B2: ATPase subunit d immunoreactivity in the same field as B1. A3: Yellow color indicates co-localization of SUCLA2 and ATPase subunit d. An almost complete absence of singly labeled structures can be observed except for the red blood cells. B3: The co-localization of SUCLA2 and ATPase subunit d is predominant even within a cell at high magnification. Scale bars = 50 µm for A1-3 and 20 µm for B1-3.

Fig. 4. The neuronal localization of SUCLA2 immunoreactivity in the human temporal cortex. A1: The distribution of SUCLA2-positive cells is similar to that of Nissl-labeled cells (red), both present throughout the temporal cortex. A2: A higher magnification image reveals that essentially all large Nissl-labeled cells with irregular shape demonstrate SUCLA2 immunolabeling (yellow cells). In contrast, small, intensely labeled round-shape cells do not exhibit SUCLA2 immunoreactivity and remain red (arrowheads). Some blood vessels are labeled green because of the peroxidase activity of the red blood cells present in the vessels in the non-perfused human tissue. A3: A high magnification confocal microscopy image demonstrating the punctuate location of SUCLA2 immunoreactivity within the cytosol of Nissl-labeled neurons whereas small glial cells do not exhibit SUCLA2 immunoreactivity. B1: The distribution of the glial marker S100 (red) is different from that of SUCLA2-positive cells (green). B2: A higher magnification image demonstrates a lack of co-localization between SUCLA2 and S100. Glial cells labeled with S100 are indicated by arrowheads. B3: High magnification confocal picture shows that SUCLA2 and S100 are located in different cell types. Scale bars: 200 µm for A1, 50 µm for A2, 20 µm for A3, 500 µm for B1, 50 µm for B2, and 20 µm for B3.

Fig. 5. The different cellular localization of SUCLA2 and GFAP. SUCLA2 labels a number of evenly distributed cells with punctuate appearance (red). GFAP-positive glial cells (green) possessing the characteristic glial
processes are also evenly distributed. These glial cells, however, are not labeled by SUCLA2 whereas SUCLA2 cells are not labeled by GFAP. Scale bar: 100 μm.

Fig. 6. A: An RT-PCR experiment demonstrates the expression of SUCLA2 but not SUCLG2 mRNA in the human temporal cortex by showing PCR products run on gel. The appearance of appropriate bands on the gel for primer pairs A-C for SUCLA2 (235, 309, and 242 bp, respectively) and primer pairs A-D for SUCLG2 (279, 387, 366, and 211 bp, respectively) in human fibroblasts indicate SUCLA2 and SUCLG2 expression in this cell type. In contrast, when the template of the PCR reaction was cDNA prepared from freshly dissected surgical human temporal cortex samples, only SUCLA2 but not SUCLG2 resulted in visible bands. B and C: Dark-field photomicrographs of human temporal cortex labeled with in situ hybridization histochemistry for SUCLA2 (B), and SUCLG2 (C). The white dots represent labeled cells. All cortical layers but not the corpus callosum (cc) is labeled for SUCLA2 (B). The intensity of labeling is highest in layers III-V whereas layers I, II, and VI contains less intensely labeled cell. In contrast, SUCLG2 labeling above the background is absent in all layers of the cerebral cortex (C). Scale bar = 1 mm.

Fig. 7. The selective SUCLA2 mRNA expression in neurons based on double labeling with in situ hybridization histochemistry for SUCLA2 and neuronal or glial markers. The distribution of Nissl-labeled cells (A) and S100-immunoreactive astrocytes (B) is shown in the human temporal cortex. The tiny autoradiography grains of the in situ hybridization signal are not visible at this low magnification. High magnification pictures demonstrate the location of autoradiography grains representing SUCLA2 mRNA in relation to Nissl-labeled cells (C), and S100-immunoreactive astrocytes (D). Black arrowheads indicate double labeled cells. Based on the larger size and fainter Nissl labeling, these cells are neurons. Above these cells, the number of autoradiography grains is more than 4. In contrast, the darker, smaller and circular-shaped glial cells indicated by white arrowheads in C are not labeled for SUCLA2 mRNA. Also, mRNA expression of SUCLA2 is absent in S100-immunoreactive astrocytes (white arrowheads) in D. Scale bars = 500 μm for A, B, and 50 μm for C, D.

Fig. 8. Immunoreactivities of the substrate-specific β subunit encoded by either SUCLA2 or SUCLG2 in tissue homogenates. A: MB signifies mouse brain (whole brain homogenates from four different animals 1, 2, 3 and 4). All other alphanumeric titles signify human brain samples obtained from regions as indicated in the panels. B: Immunoreactivity of the substrate-specific β subunit encoded by SUCLA2 in human fibroblasts from a healthy donor and a patient with a complete deletion of SUCLA2. C: Immunoreactivities of the substrate-specific β subunit encoded by either SUCLA2 or SUCLG2 in human temporal cortex samples from control subjects versus those that suffered from diabetes mellitus. For all lanes of all panels, immunoreactivity of β-actin was used as a loading control.

Table 1: Inventory of human brain samples used for Western blotting in figure 8.
Table 1A.
<table>
<thead>
<tr>
<th>Brain Sample Number (control)</th>
<th>Gender</th>
<th>Age</th>
<th>Post mortem delay</th>
<th>Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>910, 905, 907, 921, 904, 888</td>
<td>male</td>
<td>46</td>
<td>4 h</td>
<td>senile, hypertensive atherosclerosis; acute myocardial infarction</td>
</tr>
<tr>
<td>282, 298, 291, 286, 285, 305</td>
<td>male</td>
<td>66</td>
<td>4.5 h</td>
<td>cardiovascular-pulmonary insufficiency, acute lymphoid leukemia</td>
</tr>
<tr>
<td>697, 698, 713, 701, 702, 677</td>
<td>male</td>
<td>63</td>
<td>3.5 h</td>
<td>pulmonary embolism</td>
</tr>
</tbody>
</table>

Table 1B.

<table>
<thead>
<tr>
<th>Brain region</th>
<th>Sample No.</th>
<th>Sample No.</th>
<th>Sample No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frontal cortex</td>
<td>910</td>
<td>282</td>
<td>697</td>
</tr>
<tr>
<td>Cerebral white matter (frontal)</td>
<td>905</td>
<td>298</td>
<td>698</td>
</tr>
<tr>
<td>Temporal cortex</td>
<td>907</td>
<td>291</td>
<td>713</td>
</tr>
<tr>
<td>Caudate nucleus</td>
<td>921</td>
<td>286</td>
<td>701</td>
</tr>
<tr>
<td>Putamen</td>
<td>904</td>
<td>285</td>
<td>702</td>
</tr>
<tr>
<td>Cerebellar cortex</td>
<td>888</td>
<td>305</td>
<td>677</td>
</tr>
</tbody>
</table>

Table 1C.

<table>
<thead>
<tr>
<th>Brain Sample Number (control, temporal cortex)</th>
<th>Gender</th>
<th>Age</th>
<th>Post mortem delay</th>
<th>Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>648</td>
<td>female</td>
<td>72</td>
<td>4 h</td>
<td>acute myocardial infarction, earlier heart failure, atherosclerosis</td>
</tr>
<tr>
<td>481</td>
<td>female</td>
<td>89</td>
<td>2 h</td>
<td>atherosclerosis cerebri, dementia</td>
</tr>
<tr>
<td>616</td>
<td>female</td>
<td>71</td>
<td>6 h</td>
<td>stroke - cardiovascular-pulmonary insufficiency</td>
</tr>
<tr>
<td>A261</td>
<td>female</td>
<td>87</td>
<td>6 h</td>
<td>dementia, myocardial insufficiency</td>
</tr>
</tbody>
</table>

Table 1D.

<table>
<thead>
<tr>
<th>Brain Sample Number (diabetes mellitus, temporal cortex)</th>
<th>Gender</th>
<th>Age</th>
<th>Post mortem delay</th>
<th>Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>680</td>
<td>female</td>
<td>88</td>
<td>2.5 h</td>
<td>cardiac insufficiency, heart failure</td>
</tr>
<tr>
<td>525</td>
<td>female</td>
<td>70</td>
<td>6 h</td>
<td>Guillain-Barré syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>406</td>
<td>female</td>
<td>68</td>
<td>3 h</td>
<td>pneumonia, respiratory insufficiency</td>
</tr>
<tr>
<td>A89</td>
<td>female</td>
<td>79</td>
<td>6 h</td>
<td>pulmonary embolism</td>
</tr>
</tbody>
</table>